Componente hemodinámico en el glaucoma y su asociación con factores de riesgo y enfermedades cardiovasculares / Hemodynamic component in glaucoma and its association with risk factors and cardiovascular disease

Fundamento y objetivo: Se pretende estudiar la asociación del glaucoma con la enfermedad vascular, mediante 2 vías independientes: la asociación del glaucoma con las enfermedades cardiovasculares (ECV) y el estudio de las variables de hemodinámica ocular (VHO) en el glaucoma. Material y método: Se realizó un estudio transversal con 73 sujetos: 25 sin glaucoma, 28 glaucomas primarios de ángulo abierto (GPAA) y 20 glaucomas de tensión normal (GTN). Se midieron las VHO, factores de riesgo cardiovascular (FRCV) y ECV. Resultados: Se encontró un mayor porcentaje de FRCV y ECV en pacientes afectados de GPAA (p = 0,002 y p = 0,016) y GTN (p = 0,001 y p = 0,010) respecto al grupo control. En lo que respecta a las VHO, en los pacientes con GPAA encontramos menores velocidades sistólicas y diastólicas, así como mayores índices de resistencia en la arteria central de la retina (p < 0,05). Además, en ambos tipos de glaucoma encontramos índices de resistencia más elevados en la arteria ciliar posterior (p < 0,05). Conclusiones: Existe una asociación estadísticamente significativa entre la presencia de ECV y/o FRCV y la enfermedad glaucomatosa, hallazgo que se complementa con los datos de las VHO. Estos valores indican una peor perfusión ocular en los pacientes con enfermedad glaucomatosa (AU)

Background and objective: We sought to study the association of glaucoma with vascular disease, with 2 independent pathways: the association of glaucoma with cardiovascular disease (CVD) and the study of ocular hemodynamic variables (OHV) in glaucoma. Material and method: Cross-sectional study consisting of 73 patients: 25 without glaucoma, 28 primary open-angle glaucoma (POAG) and 20 normal-tension glaucoma (NTG). OHV, cardiovascular risk factors (CVRF) and CVD were determined. Results: We found a greater number of CVRF and CVD in patients affected by POAG (P = .002 and P = .016) and NTG (P = .001 and P = .010) compared to the control group. With regard to OHV, in patients suffering from POAG, we found lower systolic and diastolic velocities and higher resistance index in the central retinal artery (P < .05). Moreover, in both types of glaucoma, we found higher resistance index in the posterior ciliary artery (P < .05). Conclusions: There is a statistically significant association between the presence of CVD and/or CVRF and glaucomatous disease, a finding that is supplemented with data from the OHV. These values indicate a worst ocular perfusion in patients with glaucomatous disease (AU)

Application of interferon alpha 2b in conjunctival intraepithelial neoplasia: predictors and prognostic factors.

PURPOSE: To test the safety, tolerability, and efficacy of interferon alpha 2b for conjunctival intraepithelial neoplasia (CIN) and to evaluate the risk factors associated with its clinical outcome. A secondary goal is to identify predictors of duration of treatment to achieve good results. METHODS: A prospective, noncomparative case series. Twenty-two patients with CIN were treated with interferon alpha 2b (1 million IU/mL) 4 times daily. Patients were evaluated by slit-lamp biomicroscopy, corneal histopathology, and impression cytology and the same physician carried out the diagnosis in all cases. Patients were monitored for relapses for 48 months after interferon therapy had ended. The following statistical tests were carried out: descriptive, bivariate correlation, and survival curves. RESULTS: Topical therapy eliminated clinical signs of disease in 91% of the cases (20 of 22). The average time to CIN resolution was 3.5 months (range 1-9), with only 4 patients presenting adverse effects (1 irritative conjunctivitis and 3 punctate keratitis). None of the 4 cases experiencing adverse reactions required discontinuation of therapy. Patients living in areas with high ultraviolet radiation levels had a longer clinical resolution (4.2 months) than those living in areas with low UV levels (1.8 months, P=0.01). There was association with statistical significance between the size of the lesion at the third month and treatment duration (P=0.048). CONCLUSION: Topical interferon alpha 2b is an effective and safe treatment option for CIN. The place of residence can be a risk factor; areas like coast with higher UV levels result in a slower clinical resolution than inland areas. The size of the lesion after the third month of treatment with interferon can be a predictor of time to clinical resolution of CIN.

[Hemodynamic component in glaucoma and its association with risk factors and cardiovascular disease]. / Componente hemodinámico en el glaucoma y su asociación con factores de riesgo y enfermedades cardiovasculares.

BACKGROUND AND OBJECTIVE: We sought to study the association of glaucoma with vascular disease, with 2 independent pathways: the association of glaucoma with cardiovascular disease (CVD) and the study of ocular hemodynamic variables (OHV) in glaucoma. MATERIAL AND METHOD: Cross-sectional study consisting of 73 patients: 25 without glaucoma, 28 primary open-angle glaucoma (POAG) and 20 normal-tension glaucoma (NTG). OHV, cardiovascular risk factors (CVRF) and CVD were determined. RESULTS: We found a greater number of CVRF and CVD in patients affected by POAG (P=.002 and P=.016) and NTG (P=.001 and P=.010) compared to the control group. With regard to OHV, in patients suffering from POAG, we found lower systolic and diastolic velocities and higher resistance index in the central retinal artery (P<.05). Moreover, in both types of glaucoma, we found higher resistance index in the posterior ciliary artery (P<.05). CONCLUSIONS: There is a statistically significant association between the presence of CVD and/or CVRF and glaucomatous disease, a finding that is supplemented with data from the OHV. These values indicate a worst ocular perfusion in patients with glaucomatous disease.

"Oxygen with love" and diode laser treatment decreases comorbidity and avoidable blindness due to retinopathy of prematurity: results achieved in the past 12 years.

AIM: To determine whether the "Oxygen with Love" (OWL) and diode laser treatment provided in a neonatal intensive care unit has reduced the risk of avoidable blindness caused by retinopathy of prematurity (ROP) over the past decade. MATERIALS AND METHODS: A prospective observational cohort study was performed, in which 351 infants were examined for ROP. The inclusion conditions were as follows: preterm infants, birthweight <1500 g or <32 weeks' gestational age, and birth between 1 Jan 2000 to 31 August 2012. From mid-2009, the OWL program was implemented and the ventilation protocols for such infants were amended. We tested whether the incidence of unfavorable structural outcomes of ROP had decreased following these changes. RESULTS: From 2004 to 2012, the survival rates of younger children increased (p < 0.003). From 2005 to 2012, laser treatment rather than cryotherapy was applied, and the incidence of unfavorable structural outcomes of ROP fell from 13% to 5.6% (not significant). From 2009 to 2012, the incidence of ROP decreased from 55% to 29% (p < 0.002). From 1 August 2009 to 31 August 2012, there was less need for ablative treatment for premature infants, with the rate falling from 11.81% to 3.9% (p < 0.03). This improvement was significantly associated with a reduction in the number of days of intubation (p < 0.0017), lower rates of sepsis (p < 0.003), and improvements in postnatal weight gain (p < 0.0002). CONCLUSION: The introduction of the OWL program, together with lower rates of sepsis, improvements in postnatal weight gain, and the use of diode laser treatment, has reduced the incidence of unfavorable structural outcomes of ROP.